COVID-19: CDC, FDA and CMS Guidance
This page includes AHA Today stories and other AHA content on coronavirus COVID-19 guidance from the CDC, FDA, and CMS.
The Centers for Disease Control and Prevention credited universal testing of residents and staff of all 123 West Virginia nursing homes for SARS-CoV-2, irrespective of symptoms, as a key factor for limiting COVID-19 transmissions and reducing the pandemic鈥檚 impact on the state鈥檚 vulnerable鈥
Threatening to expel hospitals from the Medicare and Medicaid programs if they don鈥檛 report COVID-19 data to the federal government, which was outlined in a Centers for Medicare & Medicaid Services interim final rule released this week, 鈥渋s ridiculous and should be rescinded,鈥 according to a鈥
People who have been within 6 feet of someone with COVID-19 for at least 15 minutes but do not have symptoms do not need to get a COVID-19 diagnostic test unless they are 鈥渁 vulnerable individual鈥 or their health care provider or public health officials recommend it, the Centers for Disease Control鈥
The Food and Drug Administration authorized the first COVID-19 antigen test that allows health care providers to read the results in minutes directly from the testing card, similar to some pregnancy tests.
The Centers for Medicare & Medicaid Services released its national training program to prevent and control COVID-19 in Medicare- and Medicaid-certified nursing homes. The training incorporates best practices and lessons learned from COVID-19 outbreaks in nursing homes and CMS inspections, with鈥
AHA urged the Centers for Medicare & Medicaid Services to provide flexibility regarding the agency鈥檚 new COVID-19 test documentation requirement for the diagnostic-related group add-on payment.
AHA urges the Centers for Medicare & Medicaid Services to provide additional flexibility regarding the agency鈥檚 new COVID-19 test documentation requirement for the diagnostic-related group (DRG) add-on payment.
The Centers for Medicare & Medicaid Services issued an interim final rule that, among other provisions, makes collecting and reporting COVID-19-data a condition of participation for hospitals that participate in Medicare.
The Food and Drug Administration issued an emergency use authorization for investigational convalescent plasma to treat suspected or laboratory-confirmed COVID-19 in hospitalized patients.
The Food and Drug Administration authorized emergency use of a rapid point-of-care antigen test to detect SARS-CoV-2 directly from nasal swab specimens.